- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04296045
A Study to Investigate the Effect of MCE on Glucose and Insulin Responses in Healthy Males
October 17, 2022 updated by: Cambridge Glycoscience
A Randomised, Double-blind, Placebo-controlled, Cross-over Study, to Investigate the Effect of Maize Cob Extract on Post-prandial Glucose and Insulin Responses in Healthy Males
Maize Cob Extract (MCE) is intended to be used as a bulking agent in food.
The purpose of this study is to determine the glycaemic and insulinemic response of MCE consumed in isolation compared to glucose; the glycaemic and insulinemic response will also be determined for MCE alone and in combination with glucose.
This is a randomised, double-blind, single-centre trial in 10 healthy male participants.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cork, Ireland
- Atlantia Food Clinical Trials
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Be able to give written informed consent;
- Be between 18 and 60 years of age inclusive;
- Have a body mass index <30 Kg/m2;
- Have a fasting glucose level of ≤6.0 mmol/L
- Be in general good health, as determined by the investigator;
- Be willing to fast for at least 10 hours before the study visit.
Exclusion Criteria:
- The presence of any of the following criteria will exclude the participant from participating in the study:
- Are less than 18 or greater than 60 years of age;
- Recent gastroenteritis or food borne illness such as confirmed food poisoning within the past 4 weeks;
- Have taken a medication or dietary supplement that may influence GI activity within the 2-weeks prior to screening;
- Have a history of abdominal surgery (excluding appendectomy);
- Have taken anaesthesia within the past 4 weeks;
- Have taken antibiotics within the past 12-weeks;
- Have a recent history of drug and/or alcohol abuse at the time of enrolment;
- Are a smoker (defined as >5 cigarettes/week);
- Have made any major dietary change in the past 3 months;
- Have planned major changes in lifestyle (i.e. diet, dieting, exercise level, travelling) during the duration of the study;
- Have an active gastrointestinal disorder or previous gastrointestinal surgery;
- Have irritable bowel syndrome, diagnosed or undiagnosed and treated with chronic medications;
- Have a metabolic or endocrine disorder such as diabetes, thyroidism, or other metabolic disorder;
- Have a severe chronic disease i.e. cancer, renal failure, hepatitis, HIV, cirrhosis etc., or with a history of such diseases;
- Have a gastrointestinal disease i.e., chronic diarrhoea, Crohn's disease, ulcerative colitis, diverticulosis, stomach or duodenal ulcers, or with a history of such diseases;
- Are severely immunocompromised (HIV positive, transplant patient, on antirejection medications, on a systemic steroid for >30 days, or chemotherapy or radiotherapy within the last year);
- Experiences alarm features such as weight loss, rectal bleeding, recent change in bowel habit (<3 months) or abdominal pain;
- Participants who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial;
- Participant is currently receiving treatment involving experimental drugs. If the participant has been in a recent experimental trial, these must have been completed not less than 30 days prior to this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Glucose
|
Ingestion of 15g glucose in water after min 10 hours of fasting
|
EXPERIMENTAL: MCE
|
Ingestion of 15g MCE in water after min 10 hours of fasting
|
EXPERIMENTAL: MCE + Glucose
|
Ingestion of 15g glucose in water after min 10 hours of fasting
Ingestion of 15g MCE in water after min 10 hours of fasting
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference in venous glucose from incremental area under the curve (iAUC) (T-15 to T120 minutes)
Time Frame: Through intervention periods of two hours
|
Through intervention periods of two hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference in venous insulin from incremental area under the curve (iAUC) (T-15 to T120 minutes)
Time Frame: Through intervention periods of two hours
|
Through intervention periods of two hours
|
Maximal concentrations for glucose and insulin (Cmax)
Time Frame: Through intervention periods of two hours
|
Through intervention periods of two hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Thomas Nicholson, M.Phil; M.Sc, Cambridge Glycoscience
- Principal Investigator: Timothy Dinan, M.D; Ph.D; D.Sc, Atlantia Food Clinical Trials
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
July 2, 2020
Primary Completion (ACTUAL)
July 31, 2020
Study Completion (ACTUAL)
August 28, 2020
Study Registration Dates
First Submitted
March 3, 2020
First Submitted That Met QC Criteria
March 4, 2020
First Posted (ACTUAL)
March 5, 2020
Study Record Updates
Last Update Posted (ACTUAL)
October 19, 2022
Last Update Submitted That Met QC Criteria
October 17, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- CG1142
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dysglycemia
-
University of PaviaCompleted
-
Washington University School of MedicineOptiScan Biomedical CorporationTerminated
-
Joint Authority for Päijät-Häme Social and Health...RecruitingArthroplasty Complications | DysglycemiaFinland
-
University of PaviaFoundation IRCCS San Matteo HospitalRecruiting
-
Shenzhen Center for Chronic Disease ControlSun Yat-sen University; Shenzhen Qilinshan SanatoriumCompletedDyslipidemia | Dysglycemia
-
Joslin Diabetes CenterKyunghee UniversityCompletedObesity | DysglycemiaUnited States
-
Joslin Diabetes CenterAmerican Diabetes AssociationCompleted
-
University Hospital, LinkoepingRecruiting
-
Azienda Ospedaliero-Universitaria di ParmaActive, not recruitingCognitive Deficit | DysglycemiaItaly
Clinical Trials on Glucose
-
University of Texas Southwestern Medical CenterCompletedSarcoma | Neuroblastoma | Pediatric CancerUnited States
-
Children's Mercy Hospital Kansas CityWithdrawnType 1 DiabetesUnited States
-
University of Massachusetts, WorcesterNot yet recruitingPregnancy, High Risk | Type 2 Diabetes Treated With InsulinUnited States
-
Glostrup University Hospital, CopenhagenUnknown
-
Makassed General HospitalCompleted
-
US Department of Veterans AffairsEmory UniversityCompletedType 2 Diabetes Mellitus | Prediabetic StateUnited States
-
NestléCompletedHealthyNew Zealand
-
Unilever R&DLeiden University Medical CenterCompleted